{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:32:41Z","timestamp":1769146361430,"version":"3.49.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Trauma Emerg Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Osteomyelitis continues to pose significant challenges in clinical management, with no universally accepted treatment guidelines at either national or international level as of 2025. Amoxicillin\/clavulanic acid (AMC) is a widely used \u03b2-lactam antibiotic known for its safety, tolerability, and broad-spectrum activity against common osteomyelitis pathogens. This work seeks to determine whether oral AMC could serve as a viable and effective option in the management of osteomyelitis based on the current treatment landscape of osteomyelitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Preferred Reporting Items for Systematic Reviews (PRISMA) were applied during the preparation of the article. For the structured search in PubMed\n                      <jats:sup>\u00ae<\/jats:sup>\n                      , The Cochrane Library, and UpToDate\n                      <jats:sup>\u00ae<\/jats:sup>\n                      , key research questions were defined and translated into specific search terms.\u00a0Inclusion and exclusion criteria were defined using the population-intervention-comparison-outcome-study design strategy. All relevant publications available from 1981 to March 2025 were considered.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1,321 publications were identified. After applying in- and exclusion criteria - supported by automation tools \u2212\u2009104 publications were analysed. The number of primary studies specifically investigating AMC for osteomyelitis is limited. However, available data suggest that AMC is effective and demonstrates non-inferiority compared to standard reference antibiotics. Pharmacokinetic data indicate that prolonged and repeated dosing may enhance distribution into deeper compartments, including bone tissue. Reported adverse effects of AMC are generally mild to moderate, in contrast to alternative agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The analysis of the included publications and theoretical considerations on the treatment of osteomyelitis show that surgical debridement followed by long-term administration of AMC can be an effective option for empirical therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00068-025-03028-w","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:28:17Z","timestamp":1769092097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of oral amoxicillin\/clavulanic acid in the treatment of osteomyelitis: a systematic review"],"prefix":"10.1007","volume":"52","author":[{"given":"Elena Sofia Giovanna","family":"Ercolin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"B\u00e4this","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"Marche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertil","family":"Bouillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Otchwemah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"issue":"4","key":"3028_CR1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1056\/NEJM197001222820406","volume":"282","author":"FA Waldvogel","year":"1970","unstructured":"Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med. 1970;282(4):198\u2013206. https:\/\/doi.org\/10.1056\/NEJM197001222820406.","journal-title":"N Engl J Med"},{"issue":"6","key":"3028_CR2","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1086\/516149","volume":"25","author":"JT Mader","year":"1997","unstructured":"Mader JT, Shirtliff M, Calhoun JH. Staging and staging application in osteomyelitis. Clin Infect Dis. 1997;25(6):1303\u20139. https:\/\/doi.org\/10.1086\/516149.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3028_CR3","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s12879-021-06274-6","volume":"21","author":"N Walter","year":"2021","unstructured":"Walter N, Baertl S, Alt V, Rupp M. What is the burden of osteomyelitis in Germany? An analysis of inpatient data from 2008 through 2018. BMC Infect Dis. 2021;21(1):550. https:\/\/doi.org\/10.1186\/s12879-021-06274-6.","journal-title":"BMC Infect Dis"},{"key":"3028_CR4","doi-asserted-by":"publisher","unstructured":"Kremers HM, Nwojo ME, Ransom JE, Wood-Wentz CM, Melton LJ 3rd, Huddleston PM 3rd. Trends in the epidemiology of osteomyelitis: a population-based study, 1969 to 2009. J Bone Joint Surg Am. 2015;97(10):837\u201345. https:\/\/doi.org\/10.2106\/JBJS.N.01350.","DOI":"10.2106\/JBJS.N.01350"},{"key":"3028_CR5","doi-asserted-by":"crossref","unstructured":"Conterno LO, Turchi MD. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Reviews. 2013;910.1002\/14651858.CD004439.pub3.","DOI":"10.1002\/14651858.CD004439.pub3"},{"key":"3028_CR6","unstructured":"WHO Regional Office for Europe: Antimicrobial Medicines Consumption (AMC) data 2023: summary. Copenhagen. World Health Organisation Regional Office for Europe. 2024. \u201aAvailable from:\u2019https:\/\/iris.who.int\/bitstream\/handle\/10665\/379828\/WHO-EURO-2024-10997-50769-76929-eng.pdf?sequence=1 (2024). Accessed 07.11.2024."},{"key":"3028_CR7","first-page":"391","volume-title":"Arzneiverordnungs-Report 2023","author":"WV Kern","year":"2024","unstructured":"Kern WV. Bakterielle und Virale infektionserkrankungen und Mykosen. In: Ludwig WD, M\u00fchlbauer B, Seifert R, editors. Arzneiverordnungs-Report 2023. Berlin, Heidelberg: Springer; 2024. pp. 391\u20136."},{"key":"3028_CR8","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST): Breakpoint tables for interpretation of MICs and zone diameters. V\u00e4xj\u00f6. EUCAST. 2025. \u201aAvailable from:\u2019https:\/\/www.eucast.org (2025). Accessed 02.02.2025."},{"key":"3028_CR9","unstructured":"European Medicine Agency (EMA): Annex III summary of product characteristics, labeling and package leaflet [Augmentin and associated names]. Amsterdam. European Medicine Agency. 2013. \u201aAvailable from:\u2019https:\/\/www.ema.europa.eu\/en\/documents\/referral\/augmentin-article-30-annex-iii_en.pdf (2013). Accessed 27.08.2024."},{"issue":"5","key":"3028_CR10","doi-asserted-by":"publisher","first-page":"e2211321","DOI":"10.1001\/jamanetworkopen.2022.11321","volume":"5","author":"B Spellberg","year":"2022","unstructured":"Spellberg B, Aggrey G, Brennan MB, Footer B, Forrest G, Hamilton F, et al. Use of novel strategies to develop guidelines for management of pyogenic osteomyelitis in adults: A WikiGuidelines group consensus statement. JAMA Netw Open. 2022;5(5):e2211321. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.11321.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"3028_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2023.104832","volume":"54","author":"E Bonnet","year":"2024","unstructured":"Bonnet E, Maulin L, Senneville E, Castan B, Fourcade C, Loubet P, et al. Clinical practice recommendations for infectious disease management of diabetic foot infection (DFI) \u2212 2023 SPILF. Infect Dis Now. 2024;54(1):104832. https:\/\/doi.org\/10.1016\/j.idnow.2023.104832.","journal-title":"Infect Dis Now"},{"key":"3028_CR12","unstructured":"Amy C, Weintrob M. Diabetic foot infections, including osteomyelitis: Treatment. Wolters Kluwer. UpToDate. 2024. Available from:\u2019https:\/\/www.uptodate.com\/contents\/diabetic-foot-infections-including-osteomyelitis-treatment?search=osteomyelitis&source=search_result&selectedTitle=3%7E150&usage_type=default&display_rank=3#H1994297146. Accessed 11.10.2024."},{"key":"3028_CR13","unstructured":"Aaron J, Tande M. Osteomyelitis in the absence of hardware: Approach to treatment in adults. Wolter Kluwer. UpToDate. 2024. Available from:\u2019https:\/\/www.uptodate.com\/contents\/osteomyelitis-in-the-absence-of-hardware-approach-to-treatment-in-adults?source=related_link. Accessed 29.08.2024."},{"issue":"3","key":"3028_CR14","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18(3):e1003583. https:\/\/doi.org\/10.1371\/journal.pmed.1003583.","journal-title":"PLoS Med"},{"issue":"2","key":"3028_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022;18(2):e1230. https:\/\/doi.org\/10.1002\/cl2.1230.","journal-title":"Campbell Syst Rev"},{"key":"3028_CR16","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. Formulierung von klinisch relevanten Fragestellungen, Priorisierung von Endpunkten. Berlin. AWMF online; \u201aAvailable from:\u2019https:\/\/www.awmf.org\/regelwerk\/formulierung-von-klinisch-relevanten-fragestellungen Accessed 04.03.2025."},{"issue":"1","key":"3028_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10156-010-0150-9","volume":"17","author":"Japanese Society of Chemotherapy Committee on guidelines for treatment of anaerobic i, Japanese Association for Anaerobic Infection R","year":"2011","unstructured":"Japanese Society of Chemotherapy Committee on guidelines for treatment of anaerobic i, Japanese Association for Anaerobic Infection R. Chapter\u00a02\u20138. Anaerobic infections (individual fields): infections in the field of orthopedics (primarily bone and joint infections). J Infect Chemother. 2011;17(1):105\u20137. https:\/\/doi.org\/10.1007\/s10156-010-0150-9.","journal-title":"J Infect Chemother"},{"issue":"6","key":"3028_CR18","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s15010-009-8269-2","volume":"37","author":"S Esposito","year":"2009","unstructured":"Esposito S, Leone S, Bassetti M, Borre S, Leoncini F, Meani E, et al. Italian guidelines for the diagnosis and infectious disease management of osteomyelitis and prosthetic joint infections in adults. Infection. 2009;37(6):478\u201396. https:\/\/doi.org\/10.1007\/s15010-009-8269-2.","journal-title":"Infection"},{"key":"3028_CR19","first-page":"228","volume-title":"10 Knochen- und gelenkinfektionen","author":"G Mathias","year":"2019","unstructured":"Mathias G, Vossen R, Gattringer F, Thalhammer M, Militz, Hischebeth G. S2k Leitlinie-Kalkulierte parenterale initialtherapie bakterieller erkrankungen Bei erwachsenen \u2013Update 2018. editor. 10 Knochen- und gelenkinfektionen. 2 ed. AWMF online: AWMF; 2019. pp. 228\u201333. Paul-Ehrlich-Gesellschaft f\u00fcr Chemotherapie e.V. (PEG).","edition":"2"},{"issue":"4","key":"3028_CR20","first-page":"395","volume":"104","author":"C David","year":"2021","unstructured":"David C, Bury TSR, Dickman MM. Osteomyelitis: diagnosis and treatment. Am Acad Fam Physician. 2021;104(4):395\u2013402.","journal-title":"Am Acad Fam Physician"},{"issue":"1","key":"3028_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/dmrr.2699","volume":"32","author":"BA Lipsky","year":"2016","unstructured":"Lipsky BA, Aragon-Sanchez J, Diggle M, Embil J, Kono S, Lavery L, et al. IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes. Diabetes Metab Res Rev. 2016;32(1):45\u201374. https:\/\/doi.org\/10.1002\/dmrr.2699.","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"3028_CR22","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1086\/424846","volume":"39","author":"BA Lipsky","year":"2004","unstructured":"Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004;39(7):885\u2013910. https:\/\/doi.org\/10.1086\/424846.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"3028_CR23","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1093\/cid\/civ482","volume":"61","author":"EF Berbari","year":"2015","unstructured":"Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, et al. 2015 infectious diseases society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015;61(6):e26\u201346. https:\/\/doi.org\/10.1093\/cid\/civ482.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"3028_CR24","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.bjid.2013.12.005","volume":"18","author":"AL Lima","year":"2014","unstructured":"Lima AL, Oliveira PR, Carvalho VC, Cimerman S, Savio E. Diretrizes Panamericanas Para El Tratamiento de Las osteomielitis e infecciones de Tejidos Blandos G. Recommendations for the treatment of osteomyelitis. Braz J Infect Dis. 2014;18(5):526\u201334. https:\/\/doi.org\/10.1016\/j.bjid.2013.12.005.","journal-title":"Braz J Infect Dis"},{"key":"3028_CR25","unstructured":"Trisha Nicole Peel M. MBBS: Vertebral osteomyelitis: Treatment. UpToDate. Wolter Kluwer.2024. Available from:\u2019https:\/\/www.uptodate.com\/contents\/vertebral-osteomyelitis-treatment?search=osteomyelitis&source=search_result&selectedTitle=9%7E150&usage_type=default&display_rank=9. Accessed 29.08.2024."},{"key":"3028_CR26","unstructured":"Steven K, Schmitt M. FIDSA: Osteomyelitis associated with open fractures in adults. UpToDate. Wolter Kluwer. 2023. Available from:\u2019https:\/\/www.uptodate.com\/contents\/osteomyelitis-associated-with-open-fractures-in-adults?source=related_link. Accessed 29.08.2024."},{"key":"3028_CR27","unstructured":"Jessica Seidelman M. MPH: Pelvic osteomyelitis and other infections of the bony pelvis in adults. UpToDate. Wolter Kluwer. 2024. Available from:\u2019https:\/\/www.uptodate.com\/contents\/pelvic-osteomyelitis-and-other-infections-of-the-bony-pelvis-in-adults?search=osteomyelitis&source=search_result&selectedTitle=11%7E150&usage_type=default&display_rank=11. Accessed 09.12.2024."},{"issue":"6","key":"3028_CR28","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1111\/dom.13651","volume":"21","author":"K Gariani","year":"2019","unstructured":"Gariani K, Lebowitz D, Kressmann B, von Dach E, Sendi P, Waibel F, et al. Oral amoxicillin-clavulanate for treating diabetic foot infections. Diabetes Obes Metab. 2019;21(6):1483\u20136. https:\/\/doi.org\/10.1111\/dom.13651.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"3028_CR29","doi-asserted-by":"publisher","first-page":"e0211888","DOI":"10.1371\/journal.pone.0211888","volume":"14","author":"KH Park","year":"2019","unstructured":"Park KH, Kim DY, Lee YM, Lee MS, Kang KC, Lee JH, et al. Selection of an appropriate empiric antibiotic regimen in hematogenous vertebral osteomyelitis. PLoS One. 2019;14(2):e0211888. https:\/\/doi.org\/10.1371\/journal.pone.0211888.","journal-title":"PLoS One"},{"issue":"5","key":"3028_CR30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/jac\/34.5.755","volume":"34","author":"J Gisby","year":"1994","unstructured":"Gisby J, Beale AS, Bryant JE, Toseland CD. Staphylococcal osteomyelitis\u2013a comparison of co-amoxiclav with clindamycin and flucloxacillin in an experimental rat model. J Antimicrob Chemother. 1994;34(5):755\u201364. https:\/\/doi.org\/10.1093\/jac\/34.5.755.","journal-title":"J Antimicrob Chemother"},{"key":"3028_CR31","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1128\/AAC.01119-08","volume":"53","author":"CB Landersdorfer","year":"2009","unstructured":"Landersdorfer CB, Kinzig M, Bulitta JB, Hennig FF, Holzgrabe U, S\u00f6rgel F, et al. Bone penetration of amoxicillin and clavulanic acid evaluated by population pharmacokinetics and Monte Carlo simulation. Antimicrob Agents Chemother. 2009;53:2569\u201378. https:\/\/doi.org\/10.1128\/AAC.01119-08.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"3028_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/s1067-2516(09)80079-3","volume":"34","author":"DG Armstrong","year":"1995","unstructured":"Armstrong DG, Lanthier J, Lelievre P, Edelson GW. Methicillin-resistant coagulase-negative Staphylococcal osteomyelitis and its relationship to broad-spectrum oral antibiosis in a predominantly diabetic population. J Foot Ankle Surg. 1995;34(6):563\u20136. https:\/\/doi.org\/10.1016\/s1067-2516(09)80079-3.","journal-title":"J Foot Ankle Surg"},{"issue":"8","key":"3028_CR33","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s10096-014-2073-3","volume":"33","author":"G Walter","year":"2014","unstructured":"Walter G, Vernier M, Pinelli PO, Million M, Coulange M, Seng P, et al. Bone and joint infections due to anaerobic bacteria: an analysis of 61 cases and review of the literature. Eur J Clin Microbiol Infect Dis. 2014;33(8):1355\u201364. https:\/\/doi.org\/10.1007\/s10096-014-2073-3.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12","key":"3028_CR34","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1136\/bjsm.2008.050369","volume":"42","author":"HB Albert","year":"2008","unstructured":"Albert HB, Manniche C, Sorensen JS, Deleuran BW. Antibiotic treatment in patients with low-back pain associated with modic changes type 1 (bone oedema): a pilot study. Br J Sports Med. 2008;42(12):969\u201373. https:\/\/doi.org\/10.1136\/bjsm.2008.050369.","journal-title":"Br J Sports Med"},{"issue":"3","key":"3028_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/BF00301412","volume":"2","author":"PL Housden","year":"1993","unstructured":"Housden PL, Sullivan MF. Do augmentin or cefuroxime reach effective levels in lumbar vertebral discs when used prophylactically for discectomy? A preliminary report. Eur Spine J. 1993;2(3):145\u20138. https:\/\/doi.org\/10.1007\/BF00301412.","journal-title":"Eur Spine J"},{"issue":"Suppl B","key":"3028_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/jac\/24.suppl_b.93","volume":"24","author":"K Weismeier","year":"1989","unstructured":"Weismeier K, Adam D, Heilmann HD, Koeppe P. Penetration of amoxycillin\/clavulanate into human bone. J Antimicrob Chemother. 1989;24(Suppl B):93\u2013100. https:\/\/doi.org\/10.1093\/jac\/24.suppl_b.93.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"3028_CR37","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/clind\/24.4.643","volume":"24","author":"BA Lipsky","year":"1997","unstructured":"Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin Infect Dis. 1997;24(4):643\u20138. https:\/\/doi.org\/10.1093\/clind\/24.4.643.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"3028_CR38","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.mcna.2006.07.008","volume":"90","author":"SM Patel","year":"2006","unstructured":"Patel SM, Saravolatz LD. Monotherapy versus combination therapy. Med Clin North Am. 2006;90(6):1183\u201395. https:\/\/doi.org\/10.1016\/j.mcna.2006.07.008.","journal-title":"Med Clin North Am"},{"issue":"2","key":"3028_CR39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/jac\/dkx376","volume":"73","author":"F De Velde","year":"2018","unstructured":"De Velde F, De Winter BCM, Koch BCP, Van Gelder T, Mouton JW. Highly variable absorption of clavulanic acid during the day: a population pharmacokinetic analysis. J Antimicrob Chemother. 2018;73(2):469\u201376. https:\/\/doi.org\/10.1093\/jac\/dkx376.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"3028_CR40","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ejpb.2008.05.011","volume":"70","author":"W Weitschies","year":"2008","unstructured":"Weitschies W, Friedrich C, Wedemeyer RS, Schmidtmann M, Kosch O, Kinzig M, et al. Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying. Eur J Pharm Biopharm. 2008;70(2):641\u20138. https:\/\/doi.org\/10.1016\/j.ejpb.2008.05.011.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"3028_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/jac\/10.2.131","volume":"10","author":"DH Staniforth","year":"1982","unstructured":"Staniforth DH, Lillystone RJ, Jackson D. Effect of food on the bioavailability and tolerance of clavulanic acid\/amoxycillin combination. J Antimicrob Chemother. 1982;10(2):131\u20139. https:\/\/doi.org\/10.1093\/jac\/10.2.131.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"3028_CR42","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1007\/s10620-016-4121-6","volume":"61","author":"AS deLemos","year":"2016","unstructured":"deLemos AS, Ghabril M, Rockey DC, Gu J, Barnhart HX, Fontana RJ, et al. Amoxicillin-clavulanate-induced liver injury. Dig Dis Sci. 2016;61(8):2406\u201316. https:\/\/doi.org\/10.1007\/s10620-016-4121-6.","journal-title":"Dig Dis Sci"},{"issue":"11","key":"3028_CR43","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1111\/j.1572-0241.2007.01456.x","volume":"102","author":"K Jinjuvadia","year":"2007","unstructured":"Jinjuvadia K, Kwan W, Fontana RJ. Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol. 2007;102(11):2437\u201343. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01456.x.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"3028_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/01.meg.0000250581.77865.68","volume":"19","author":"SH Hussaini","year":"2007","unstructured":"Hussaini SH, O\u2019Brien CS, Despott EJ, Dalton HR. Antibiotic therapy: a major cause of drug-induced jaundice in Southwest England. Eur J Gastroenterol Hepatol. 2007;19(1):15\u201320. https:\/\/doi.org\/10.1097\/01.meg.0000250581.77865.68.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"3028_CR45","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","volume":"129","author":"RJ Andrade","year":"2005","unstructured":"Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512\u201321. https:\/\/doi.org\/10.1016\/j.gastro.2005.05.006.","journal-title":"Gastroenterology"},{"issue":"5","key":"3028_CR46","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/gut.47.5.717","volume":"47","author":"J O\u2019Donohue","year":"2000","unstructured":"O\u2019Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut. 2000;47(5):717\u201320. https:\/\/doi.org\/10.1136\/gut.47.5.717.","journal-title":"Gut"},{"issue":"12","key":"3028_CR47","doi-asserted-by":"publisher","first-page":"638","DOI":"10.5694\/j.1326-5377.1995.tb126049.x","volume":"162","author":"JA Thomson","year":"1995","unstructured":"Thomson JA, Fairley CK, Ugoni AM, Forbes AB, Purcell PM, Desmond PV, et al. Risk factors for the development of amoxycillin-clavulanic acid associated jaundice. Med J Aust. 1995;162(12):638\u201340. https:\/\/doi.org\/10.5694\/j.1326-5377.1995.tb126049.x.","journal-title":"Med J Aust"},{"issue":"3","key":"3028_CR48","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/gut.33.3.368","volume":"33","author":"D Larrey","year":"1992","unstructured":"Larrey D, Vial T, Micaleff A, Babany G, Morichau-Beauchant M, Michel H, et al. Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut. 1992;33(3):368\u201371. https:\/\/doi.org\/10.1136\/gut.33.3.368.","journal-title":"Gut"},{"issue":"10","key":"3028_CR49","doi-asserted-by":"publisher","first-page":"698","DOI":"10.5694\/j.1326-5377.1991.tb121267.x","volume":"154","author":"FS Wong","year":"1991","unstructured":"Wong FS, Ryan J, Dabkowski P, Dudley FJ, Sewell RB, Smallwood RA. Augmentin-induced jaundice. Med J Aust. 1991;154(10):698\u2013701. https:\/\/doi.org\/10.5694\/j.1326-5377.1991.tb121267.x.","journal-title":"Med J Aust"},{"issue":"4","key":"3028_CR50","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/0016-5085(89)91633-8","volume":"96","author":"KR Reddy","year":"1989","unstructured":"Reddy KR, Brillant P, Schiff ER. Amoxicillin-clavulanate potassium-associated cholestasis. Gastroenterology. 1989;96(4):1135\u201341. https:\/\/doi.org\/10.1016\/0016-5085(89)91633-8.","journal-title":"Gastroenterology"},{"issue":"2","key":"3028_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/157488406776872514","volume":"1","author":"P Zapater","year":"2006","unstructured":"Zapater P, Moreu R, Horga JF. The diagnosis of drug-induced liver disease. Curr Clin Pharmacol. 2006;1(2):207\u201317. https:\/\/doi.org\/10.2174\/157488406776872514.","journal-title":"Curr Clin Pharmacol"},{"issue":"1","key":"3028_CR52","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1038\/s41598-020-61872-9","volume":"10","author":"O Alhaddad","year":"2020","unstructured":"Alhaddad O, Elsabaawy M, Abdelsameea E, Abdallah A, Shabaan A, Ehsan N, et al. Presentations, causes and outcomes of drug-induced liver injury in Egypt. Sci Rep. 2020;10(1):5124. https:\/\/doi.org\/10.1038\/s41598-020-61872-9.","journal-title":"Sci Rep"},{"issue":"4 Pt B","key":"3028_CR53","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.bbadis.2017.08.033","volume":"1864","author":"M Visentin","year":"2018","unstructured":"Visentin M, Lenggenhager D, Gai Z, Kullak-Ublick GA. Drug-induced bile duct injury. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2018;1864(4 Pt B):1498\u2013506. https:\/\/doi.org\/10.1016\/j.bbadis.2017.08.033.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"issue":"3","key":"3028_CR54","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.yrtph.2015.05.004","volume":"72","author":"A Suzuki","year":"2015","unstructured":"Suzuki A, Yuen NA, Ilic K, Miller RT, Reese MJ, Brown HR, et al. Comedications alter drug-induced liver injury reporting frequency: data mining in the WHO VigiBase. Regul Toxicol Pharmacol. 2015;72(3):481\u201390. https:\/\/doi.org\/10.1016\/j.yrtph.2015.05.004.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"6","key":"3028_CR55","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1002\/hep.24022","volume":"52","author":"CM Hunt","year":"2010","unstructured":"Hunt CM. Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review. Hepatology. 2010;52(6):2216\u201322. https:\/\/doi.org\/10.1002\/hep.24022.","journal-title":"Hepatology"},{"issue":"6","key":"3028_CR56","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/hep.21424","volume":"44","author":"RJ Andrade","year":"2006","unstructured":"Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz B, Borraz Y, Pachkoria K, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology. 2006;44(6):1581\u20138. https:\/\/doi.org\/10.1002\/hep.21424.","journal-title":"Hepatology"},{"issue":"4","key":"3028_CR57","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/hep.21324","volume":"44","author":"MI Lucena","year":"2006","unstructured":"Lucena MI, Andrade RJ, Fern\u00e1ndez MC, Pachkoria K, Pelaez G, Dur\u00e1n JA, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006;44(4):850\u20136. https:\/\/doi.org\/10.1002\/hep.21324.","journal-title":"Hepatology"},{"issue":"1","key":"3028_CR58","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0168-8278(95)80262-2","volume":"22","author":"ML Hautekeete","year":"1995","unstructured":"Hautekeete ML, Brenard R, Horsmans Y, Henrion J, Verbist L, Derue G, et al. Liver injury related to amoxycillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations. J Hepatol. 1995;22(1):71\u20137. https:\/\/doi.org\/10.1016\/0168-8278(95)80262-2.","journal-title":"J Hepatol"},{"issue":"2","key":"3028_CR59","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/cpt.2930","volume":"114","author":"S Gu","year":"2023","unstructured":"Gu S, Rajendiran G, Forest K, Tran TC, Denny JC, Larson EA, et al. Drug-induced liver injury with commonly used antibiotics in the All of Us Research Program. Clin Pharmacol Ther. 2023;114(2):404\u201312. https:\/\/doi.org\/10.1002\/cpt.2930.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"3028_CR60","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1177\/0960327115606529","volume":"34","author":"A Tailor","year":"2015","unstructured":"Tailor A, Faulkner L, Naisbitt DJ, Park BK. The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury. Hum Exp Toxicol. 2015;34(12):1310\u20137. https:\/\/doi.org\/10.1177\/0960327115606529.","journal-title":"Hum Exp Toxicol"},{"issue":"2","key":"3028_CR61","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/15376516.2018.1528651","volume":"29","author":"OT Oyebode","year":"2019","unstructured":"Oyebode OT, Adebiyi OR, Olorunsogo OO. Toxicity of some broad-spectrum antibacterials in normal rat liver: the role of mitochondrial membrane permeability transition pore. Toxicol Mech Methods. 2019;29(2):128\u201337. https:\/\/doi.org\/10.1080\/15376516.2018.1528651.","journal-title":"Toxicol Mech Methods"},{"key":"3028_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107183","volume":"203","author":"JM Pinazo-Bandera","year":"2024","unstructured":"Pinazo-Bandera JM, Niu H, Alvarez-Alvarez I, Medina-Caliz I, Del Campo-Herrera E, Ortega-Alonso A, et al. Rechallenge in idiosyncratic drug-induced liver injury: an analysis of cases in two large prospective registries according to existing definitions. Pharmacol Res. 2024;203:107183. https:\/\/doi.org\/10.1016\/j.phrs.2024.107183.","journal-title":"Pharmacol Res"},{"issue":"5","key":"3028_CR63","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/ageing\/afv072","volume":"44","author":"D Gillespie","year":"2015","unstructured":"Gillespie D, Hood K, Bayer A, Carter B, Duncan D, Espinasse A, et al. Antibiotic prescribing and associated diarrhoea: a prospective cohort study of care home residents. Age Ageing. 2015;44(5):853\u201360. https:\/\/doi.org\/10.1093\/ageing\/afv072.","journal-title":"Age Ageing"},{"issue":"Suppl 2","key":"3028_CR64","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.ijantimicag.2007.09.002","volume":"30","author":"R Bax","year":"2007","unstructured":"Bax R. Development of a twice daily dosing regimen of amoxicillin\/clavulanate. Int J Antimicrob Agents. 2007;30(Suppl 2):S118-21. https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.09.002.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"3028_CR65","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/01.mpg.0000161041.80953.9e","volume":"41","author":"DM Spiro","year":"2005","unstructured":"Spiro DM, Schmidt JM, Arnold DH, Cartner SC, Yagmurlu A. Antibiotic-induced mesenteric adenopathy in an intussusception mouse model: a randomized, controlled trial. J Pediatr Gastroenterol Nutr. 2005;41(1):39\u201343. https:\/\/doi.org\/10.1097\/01.mpg.0000161041.80953.9e.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"3028_CR66","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0002-9343(92)90232-z","volume":"93","author":"AE Camacho","year":"1992","unstructured":"Camacho AE, Cobo R, Otte J, Spector SL, Lerner CJ, Garrison NA, et al. Clinical comparison of cefuroxime axetil and amoxicillin\/clavulanate in the treatment of patients with acute bacterial maxillary sinusitis. Am J Med. 1992;93(3):271\u20136. https:\/\/doi.org\/10.1016\/0002-9343(92)90232-z.","journal-title":"Am J Med"},{"issue":"6","key":"3028_CR67","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1128\/AAC.35.6.1085","volume":"35","author":"F Caron","year":"1991","unstructured":"Caron F, Ducrotte P, Lerebours E, Colin R, Humbert G, Denis P. Effects of amoxicillin-clavulanate combination on the motility of the small intestine in human beings. Antimicrob Agents Chemother. 1991;35(6):1085\u20138. https:\/\/doi.org\/10.1128\/AAC.35.6.1085.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"3028_CR68","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1111\/bcp.14328","volume":"86","author":"L Thomas","year":"2020","unstructured":"Thomas L, Le Beller C, Trenque T, Michot J, Zenut M, Letavernier E, et al. Amoxicillin-induced crystal nephropathy: A nationwide French pharmacovigilance databases study. Br J Clin Pharmacol. 2020;86(11):2256\u201365. https:\/\/doi.org\/10.1111\/bcp.14328.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"3028_CR69","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1093\/jac\/dkw166","volume":"71","author":"H Walker","year":"2016","unstructured":"Walker H, Patton A, Bayne G, Marwick C, Sneddon J, Davey P, et al. Reduction in post-operative acute kidney injury following a change in antibiotic prophylaxis policy for orthopaedic surgery: an observational study. J Antimicrob Chemother. 2016;71(9):2598\u2013605. https:\/\/doi.org\/10.1093\/jac\/dkw166.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"3028_CR70","doi-asserted-by":"publisher","first-page":"177","DOI":"10.18176\/jiaci.0896","volume":"34","author":"NP Freundt-Serpa","year":"2024","unstructured":"Freundt-Serpa NP, Salas-Cassinello M, Gonzalo-Fernandez A, Marchan-Pinedo N, Dona I, Serrano-Garcia I, et al. Deconstructing adverse reactions to amoxicillin- clavulanic acid: the importance of time of onset. J Investig Allergol Clin Immunol. 2024;34(3):177\u201387. https:\/\/doi.org\/10.18176\/jiaci.0896.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"1","key":"3028_CR71","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000446961","volume":"170","author":"R Confino-Cohen","year":"2016","unstructured":"Confino-Cohen R, Rosman Y, Lachover I, Meir Shafrir K, Goldberg A. The importance of amoxicillin and amoxicillin-Clavulanate determinants in the diagnosis of immediate allergic reactions to beta-Lactams. Int Arch Allergy Immunol. 2016;170(1):62\u20136. https:\/\/doi.org\/10.1159\/000446961.","journal-title":"Int Arch Allergy Immunol"},{"issue":"4","key":"3028_CR72","first-page":"409","volume":"77","author":"CT Tee","year":"2022","unstructured":"Tee CT, Abdullah NH, Kristummoonthy P, Lee CS. Severe cutaneous adverse reactions: a 5-year retrospective study at hospital Melaka, Malaysia, from December 2014 to February 2020. Med J Malaysia. 2022;77(4):409\u201314.","journal-title":"Med J Malaysia"},{"issue":"3","key":"3028_CR73","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/pds.4707","volume":"28","author":"RE Chandler","year":"2019","unstructured":"Chandler RE. Increased risk for aseptic meningitis after amoxicillin or amoxicillin-clavulanic acid in males: a signal revealed by subset disproportionality analysis within a global database of suspected adverse drug reactions. Pharmacoepidemiol Drug Saf. 2019;28(3):389\u201395. https:\/\/doi.org\/10.1002\/pds.4707.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3028_CR74","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.ijcard.2016.09.066","volume":"224","author":"F Renda","year":"2016","unstructured":"Renda F, Marotta E, Landoni G, Belletti A, Cuconato V, Pani L. Kounis syndrome due to antibiotics: a global overview from pharmacovigilance databases. Int J Cardiol. 2016;224:406\u201311. https:\/\/doi.org\/10.1016\/j.ijcard.2016.09.066.","journal-title":"Int J Cardiol"},{"issue":"12","key":"3028_CR75","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1111\/bcp.14118","volume":"85","author":"S Daniel","year":"2019","unstructured":"Daniel S, Doron M, Fishman B, Koren G, Lunenfeld E, Levy A. The safety of amoxicillin and clavulanic acid use during the first trimester of pregnancy. Br J Clin Pharmacol. 2019;85(12):2856\u201363. https:\/\/doi.org\/10.1111\/bcp.14118.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"3028_CR76","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/s0301-2115(00)00545-5","volume":"97","author":"AE Czeizel","year":"2001","unstructured":"Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case-control teratologic study. Eur J Obstet Gynecol Reprod Biol. 2001;97(2):188\u201392. https:\/\/doi.org\/10.1016\/s0301-2115(00)00545-5.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"3028_CR77","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/cid\/ciu914","volume":"60","author":"HW Chou","year":"2015","unstructured":"Chou HW, Wang JL, Chang CH, Lai CL, Lai MS, Chan KA. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and beta-lactam\/beta-lactamase inhibitors: a Taiwanese nationwide study. Clin Infect Dis. 2015;60(4):566\u201377. https:\/\/doi.org\/10.1093\/cid\/ciu914.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"3028_CR78","doi-asserted-by":"publisher","first-page":"e70036","DOI":"10.1002\/pds.70036","volume":"33","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Fan M, Tsie NTY, Lee EHM, Chang WC, Chen EYH, et al. Association between oral fluoroquinolones and neuropsychiatric events: Self-Controlled case series with active comparator design. Pharmacoepidemiol Drug Saf. 2024;33(10):e70036. https:\/\/doi.org\/10.1002\/pds.70036.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3028_CR79","doi-asserted-by":"publisher","first-page":"469580241273323","DOI":"10.1177\/00469580241273323","volume":"61","author":"KW Mwamwitwa","year":"2024","unstructured":"Mwamwitwa KW, Bukundi EM, Maganda BA, Munishi C, Fimbo AM, Buma D, et al. Adverse drug reactions resulting from the use of chiral medicines Amoxicillin, Amoxicillin-Clavulanic Acid, and ceftriaxone: A mixed Prospective-Retrospective cohort study. Inquiry. 2024;61:469580241273323. https:\/\/doi.org\/10.1177\/00469580241273323.","journal-title":"Inquiry"},{"issue":"7","key":"3028_CR80","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/jphp.12920","volume":"70","author":"NA Charoo","year":"2018","unstructured":"Charoo NA, Rahman Z, Ali AA. Is the demonstration of bioequivalence for clavulanic acid required in amoxicillin-clavulanic acid orally administered immediate-release products? J Pharm Pharmacol. 2018;70(7):883\u201392. https:\/\/doi.org\/10.1111\/jphp.12920.","journal-title":"J Pharm Pharmacol"},{"issue":"5","key":"3028_CR81","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jhsa.2014.01.021","volume":"39","author":"WL Richardson","year":"2014","unstructured":"Richardson WL, Hammert WC. Adverse effects of common oral antibiotics. J Hand Surg Am. 2014;39(5):989\u201391. https:\/\/doi.org\/10.1016\/j.jhsa.2014.01.021.","journal-title":"J Hand Surg Am"},{"issue":"4","key":"3028_CR82","first-page":"139","volume":"6","author":"U Gresser","year":"2001","unstructured":"Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects - review of the literature. Eur J Med Res. 2001;6(4):139\u201349.","journal-title":"Eur J Med Res"},{"issue":"1","key":"3028_CR83","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jac\/35.1.129","volume":"35","author":"RG Masterton","year":"1995","unstructured":"Masterton RG, Bochsler JA. High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. J Antimicrob Chemother. 1995;35(1):129\u201337. https:\/\/doi.org\/10.1093\/jac\/35.1.129.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl D","key":"3028_CR84","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/jac\/26.suppl_d.75","volume":"26","author":"CM Rademaker","year":"1990","unstructured":"Rademaker CM, Sips AP, Beumer HM, Hoepelman IM, Overbeek BP, Mollers MJ, et al. A double-blind comparison of low-dose ofloxacin and amoxycillin\/clavulanic acid in acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1990;26(Suppl D):75\u201381. https:\/\/doi.org\/10.1093\/jac\/26.suppl_d.75.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl D","key":"3028_CR85","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/jac\/26.suppl_d.83","volume":"26","author":"R Khajotia","year":"1990","unstructured":"Khajotia R, Drlicek M, Vetter N. A comparative study of ofloxacin and amoxycillin\/clavulanate in hospitalized patients with lower respiratory tract infections. J Antimicrob Chemother. 1990;26(Suppl D):83\u201391. https:\/\/doi.org\/10.1093\/jac\/26.suppl_d.83.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"3028_CR86","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/jac\/10.1.67","volume":"10","author":"AP Ball","year":"1982","unstructured":"Ball AP, Mehtar S, Watson A. Clinical efficacy and tolerance of augmentin in soft tissue infection. J Antimicrob Chemother. 1982;10(1):67\u201374. https:\/\/doi.org\/10.1093\/jac\/10.1.67.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"3028_CR87","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/bf01645083","volume":"16","author":"W B\u00fcchi","year":"1988","unstructured":"B\u00fcchi W, Casey PA. Experience with parenteral and sequential parenteral-oral amoxicillin\/clavulanate (augmentin) in hospitalized patients. Infection. 1988;16(5):306\u201312. https:\/\/doi.org\/10.1007\/bf01645083.","journal-title":"Infection"},{"issue":"1","key":"3028_CR88","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/jac\/dkm111","volume":"60","author":"F Salvo","year":"2007","unstructured":"Salvo F, Polimeni G, Moretti U, Conforti A, Leone R, Leoni O, et al. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother. 2007;60(1):121\u20136. https:\/\/doi.org\/10.1093\/jac\/dkm111.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"3028_CR89","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ijantimicag.2005.07.017","volume":"26","author":"P Giordano","year":"2005","unstructured":"Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous\/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents. 2005;26(5):357\u201365. https:\/\/doi.org\/10.1016\/j.ijantimicag.2005.07.017.","journal-title":"Int J Antimicrob Agents"},{"key":"3028_CR90","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST): Public consultation on Proposed change in breakpoints for aminopenicillins and enterococci. V\u00e4xj\u00f6. EUCAST. 2024. \u201aAvailable from:\u2019https:\/\/www.eucast.org\/eucast_news\/news_singleview?tx_ttnews%5Btt_news%5D=587&cHash=3f669f4afd2f8735831a8c899dd43430. Accessed 03.03.2025."},{"key":"3028_CR91","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST): General consultation on Aminopenicillin breakpoints for Enterobacterales. V\u00e4xj\u00f6. EUCAST. 2021. Available from:\u2019https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Consultation\/2021\/Aminopenicillins_and_Enterobacterales_General_consultation_November_2021.pdf. Accessed 03.03.2025."},{"issue":"2","key":"3028_CR92","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","volume":"48","author":"CB Landersdorfer","year":"2009","unstructured":"Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, S\u00f6rge F. Penetration of antibacterials into bone pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet. 2009;48(2):89\u2013124. https:\/\/doi.org\/10.2165\/00003088-200948020-00002.","journal-title":"Clin Pharmacokinet"},{"key":"3028_CR93","doi-asserted-by":"crossref","unstructured":"Landersdorfer CB, Bulitta JB, S\u00f6rgel F. Pharmacokinetics and Pharmacodynamics of Antibiotics in Bone. In: Bone and Joint Infections (From Microbiology to Diagnostics and Treatment). 1 ed. John Wiley & Sons, Inc.; 2015.","DOI":"10.1002\/9781118581742.ch3"},{"key":"3028_CR94","unstructured":"Universit\u00e4tsbibliothek B. Drug Overviews: PubPharm Narrative: Amoxicillin. Braunschweig. PubPharm; \u201aAvailable from:\u2019https:\/\/narrative.pubpharm.de\/drug_overview\/?drug=Amoxicillin. Accessed 01.02.2025."},{"key":"3028_CR95","unstructured":"Universit\u00e4tsbibliothek B. Drug Overviews: PubPharm Narrative: Clavulanic Acid. Braunschweig. PubPharm; \u201aAvailable from:https:\/\/narrative.pubpharm.de\/drug_overview\/?drug=Clavulanic%20Acid. Accessed 01.02.2025."},{"issue":"5","key":"3028_CR96","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa1710926","volume":"380","author":"HK Li","year":"2019","unstructured":"Li HK, Rombach I, Zambellas R, Walker AS, McNally MA, Atkins BL, et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019;380(5):425\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1710926.","journal-title":"N Engl J Med"},{"issue":"3","key":"3028_CR97","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamasurg.2024.6439","volume":"160","author":"C Research","year":"2025","unstructured":"Major Extremity Trauma, Research C, Obremskey WT, O\u2019Toole RV, Morshed S, Tornetta P 3, et al. Oral vs intravenous antibiotics for fracture-related infections: the POvIV randomized clinical trial. JAMA Surg. 2025;160(3):276\u201384. https:\/\/doi.org\/10.1001\/jamasurg.2024.6439.","journal-title":"JAMA Surg"},{"key":"3028_CR98","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","volume":"81","author":"AK Thabit","year":"2019","unstructured":"Thabit AK, Fatani DF, Bamakhrama MS, Barnawi OA, Basudan LO, Alhejaili SF. Antibiotic penetration into bone and joints: an updated review. Int J Infect Dis. 2019;81:128\u201336. https:\/\/doi.org\/10.1016\/j.ijid.2019.02.005.","journal-title":"Int J Infect Dis"},{"key":"3028_CR99","unstructured":"Lexicomp. Wolters Kluwer Health, Hudson (OH), UpToDate\u00ae Lexidrug\u2122 Multinational. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/multinat_f\/4668586?cesid=11NHvKQoQdV&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Damoxicillin%2Bund%2Bclavulanat%26t%3Dname%26acs%3Dtrue%26acq%3Damox&continue. Accessed 01.02.2025."},{"key":"3028_CR100","unstructured":"Lexicomp. Wolters Kluwer Health, Hudson (OH), UpToDate\u00ae Lexidrug\u2122 Multinational. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/multinat_f\/4669280?cesid=93RrX82aFZv&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dclindamycin%2Bsystemisch%26t%3Dname%26acs%3Dtrue%26acq%3Dclin#drug-shortages. Accessed 01.02.2025."},{"key":"3028_CR101","unstructured":"Lexicomp. Wolters Kluwer Health, Hudson (OH), UpToDate\u00ae Lexidrug\u2122 Multinational. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/multinat_f\/4669001?cesid=4NnYaPFXE0X&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dciprofloxacin%26t%3Dname%26acs%3Dfalse%26acq%3Dciproflo. Accessed 01.02.2025."},{"issue":"5","key":"3028_CR102","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1128\/AAC.02176-12","volume":"57","author":"KA Brown","year":"2013","unstructured":"Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated clostridium difficile infection. Antimicrob Agents Chemother. 2013;57(5):2326\u201332. https:\/\/doi.org\/10.1128\/AAC.02176-12.","journal-title":"Antimicrob Agents Chemother"},{"key":"3028_CR103","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.anaerobe.2018.01.011","volume":"50","author":"MJ Nasiri","year":"2018","unstructured":"Nasiri MJ, Goudarzi M, Hajikhani B, Ghazi M, Goudarzi H, Pouriran R. Clostridioides (Clostridium) difficile infection in hospitalized patients with antibiotic-associated diarrhea: a systematic review and meta-analysis. Anaerobe. 2018;50:32\u20137. https:\/\/doi.org\/10.1016\/j.anaerobe.2018.01.011.","journal-title":"Anaerobe"},{"key":"3028_CR104","unstructured":"Lexicomp. Wolters Kluwer Health, Hudson (OH), UpToDate\u00ae Lexidrug\u2122 Multinational. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/multinat_f\/4669379?cesid=2ayi8mLCqyo&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dcotrimoxa%26t%3Dname%26acs%3Dfalse%26acq%3Dcotrimoxa. Accessed 01.02.2025."},{"key":"3028_CR105","unstructured":"Lexicomp. Wolters Kluwer Health, Hudson (OH), UpToDate\u00ae Lexidrug\u2122 Multinational. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/multinat_f\/4668991?cesid=8CwdjrK99UO&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Drifampicin%26t%3Dname%26acs%3Dfalse%26acq%3Drifampicin. Accessed 01.02.2025."}],"container-title":["European Journal of Trauma and Emergency Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00068-025-03028-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00068-025-03028-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00068-025-03028-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:28:25Z","timestamp":1769092105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00068-025-03028-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3028"],"URL":"https:\/\/doi.org\/10.1007\/s00068-025-03028-w","relation":{},"ISSN":["1863-9941"],"issn-type":[{"value":"1863-9941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Sequence information"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}